About oculis holding - OCS
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
OCS At a Glance
Oculis Holding AG
Bahnhofstrasse 20
Zug, Zug 6300
| Phone | 41-41-711-39-60 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -97,399,976.06 | |
| Sector | Health Technology | Employees | 49 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
OCS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 9.167 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.943 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
OCS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,987,754.614 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
OCS Liquidity
| Current Ratio | 2.371 |
| Quick Ratio | 2.371 |
| Cash Ratio | 2.23 |
OCS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -72.505 |
| Return on Equity | -101.281 |
| Return on Total Capital | -118.381 |
| Return on Invested Capital | -100.514 |
OCS Capital Structure
| Total Debt to Total Equity | 1.608 |
| Total Debt to Total Capital | 1.583 |
| Total Debt to Total Assets | 0.98 |
| Long-Term Debt to Equity | 1.179 |
| Long-Term Debt to Total Capital | 1.16 |